Oxyntomodulin is a naturally occurring 37 amino acid peptide hormone found in the colon, produced by the oxyntic (fundic) cells of the oxyntic (fundic) mucosa. It has been found to suppress appetite. A recent study has found that it can be used as a weight loss treatment.
The mechanism of action of oxyntomodulin is not well understood. It is known to bind both the GLP-1 receptor and the glucagon receptor but it is not known whether the effects of the hormone are mediated through these receptors or through an unidentified receptor.
Thiakis , a biotechnology company based in London and founded by Professor Steve Bloom and Dr John Burt, is developing a novel analogue of oxyntomodulin for the treatment of obesity.
- Weight loss study Telegraph
- Scientists Discoover New Weapon Against Obesity-Oxytomodulin health.dailynewscentral.com
- BBC News story: New way to treat obesity heralded, April 26, 2006
- Wynne K, Park AJ, Small CJ; et al. (2006). "Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial". International journal of obesity (2005). 30 (12): 1729–36. doi:10.1038/sj.ijo.0803344. PMID 16619056.
|File:AlphaHelixSection (yellow).svg||This biochemistry article is a stub. You can help Wikipedia by expanding it.|